Durvalumab extends survival in stage III non-small cell lung CA
(HealthDay)—Durvalumab results in significantly longer overall survival than placebo among patients with stage III, unresectable non-small cell lung cancer who did not have disease progression after concurrent chemoradiotherapy, ...
Oct 30, 2018
0
0